ADITXT INC (ADTX) Stock Price & Overview
NASDAQ:ADTX • US0070258852
Current stock price
The current stock price of ADTX is 0.7944 USD. Today ADTX is down by -11.72%. In the past month the price decreased by -77.11%. In the past year, price decreased by -99.98%.
ADTX Key Statistics
- Market Cap
- 413.088K
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -101,947.18
- Dividend Yield
- N/A
ADTX Stock Performance
ADTX Stock Chart
ADTX Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ADTX. When comparing the yearly performance of all stocks, ADTX is a bad performer in the overall market: 99.7% of all stocks are doing better.
ADTX Earnings
ADTX Forecast & Estimates
For the next year, analysts expect an EPS growth of -2096.63% and a revenue growth 1584.79% for ADTX
ADTX Groups
Sector & Classification
ADTX Financial Highlights
Over the last trailing twelve months ADTX reported a non-GAAP Earnings per Share(EPS) of -101947.18. The EPS decreased by -43.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -357.97% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ADTX Ownership
ADTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ADTX
Company Profile
Aditxt Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Richmond, Virginia and currently employs 26 full-time employees. The company went IPO on 2020-06-19. Aditxt, Inc. is a social innovation platform dedicated to accelerating promising health innovations. The company develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. The company also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
Company Info
IPO: 2020-06-19
ADITXT INC
737 N. Fifth Street, Suite 200
Richmond VIRGINIA 94043 US
CEO: Amro Albanna
Employees: 26
Phone: 19094880844
ADITXT INC / ADTX FAQ
What does ADTX do?
Aditxt Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Richmond, Virginia and currently employs 26 full-time employees. The company went IPO on 2020-06-19. Aditxt, Inc. is a social innovation platform dedicated to accelerating promising health innovations. The company develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. The company also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
Can you provide the latest stock price for ADITXT INC?
The current stock price of ADTX is 0.7944 USD. The price decreased by -11.72% in the last trading session.
Does ADTX stock pay dividends?
ADTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of ADTX stock?
ADTX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the Price/Earnings (PE) ratio of ADITXT INC (ADTX)?
ADITXT INC (ADTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-101947.18).
Can you provide the ownership details for ADTX stock?
You can find the ownership structure of ADITXT INC (ADTX) on the Ownership tab.